"rationale","name","uuid:ID","instanceType","id","description","label"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","f4efb8a8-4ef2-49a6-9007-aaefc3b705e6","StudyDesign","StudyDesign_1","The main design for the study",""
